Cardiovascular collaboration
Cryptome Pharmaceuticals has signed a memorandum of understanding with the University of Queensland's Institute for Molecular Biosciences (IMB) to collaborate on the identification of potential therapeutics for cardiovascular disease.
The IMB will provide Cryptome with high value compound libraries, which Cryptome will screen for potential activity using its proprietary Cryptomics platform technology. The Cryptomics drug discovery platform is based on finding small protein fragments with previously undiscovered therapeutic activities. These fragments are generated, screened and identified using the Cryptomics systematic high-throughput approach.
Horizon Europe negotiations conclude
Once associated, Australian researchers and entities will be able to access Horizon Europe...
AusBiotech responds to Budget 2026–27
The life sciences industry body has responded to measures set out in the Australian...
AI.gov.au launches to help safe and responsible AI use
Providing guidance, tools and resources to help Australian businesses use AI safely, the...
